JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spence, A. M.
Right arrow Articles by Krohn, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spence, A. M.
Right arrow Articles by Krohn, K. A.
Journal of Nuclear Medicine Vol. 45 No. 10 1653-1659
© 2004 by Society of Nuclear Medicine


Clinical Investigations

18F-FDG PET of Gliomas at Delayed Intervals: Improved Distinction Between Tumor and Normal Gray Matter

Alexander M. Spence, MD1, Mark Muzi, MS2, David A. Mankoff, MD, PhD2, S. Finbarr O’Sullivan, PhD3, Jeanne M. Link, PhD2, Thomas K. Lewellen, PhD2, Barbara Lewellen, MS2, Pam Pham, BS2, Satoshi Minoshima, MD, PhD2, Kristin Swanson, PhD4 and Kenneth A. Krohn, PhD2

1 Department of Neurology, University of Washington School of Medicine, Seattle, Washington
2 Department of Radiology, University of Washington School of Medicine, Seattle, Washington
3 Department of Statistics, University of Washington School of Medicine, Seattle, Washington
4 Department of Pathology, University of Washington School of Medicine, Seattle, Washington

We hypothesized that delineation of gliomas from gray matter with 18F-FDG PET could be improved by extending the interval between 18F-FDG administration and PET data acquisition. The purposes of this study were, first, to analyze standard and delayed 18F-FDG PET images visually and quantitatively to determine whether definition of tumor improved at later imaging times and, second, to investigate the dynamics of model-derived kinetic rate constants, particularly k4. Methods: Nineteen adult patients with supratentorial gliomas were imaged from 0 to 90 min and once or twice later at 180–480 min after injection. In 15 patients, arterial sampling provided the early input function. Venous sampling provided the remaining curve to the end of the imaging sequence. Standardized uptake value (SUV) was calculated as tissue concentration of tracer per injected tracer dose per body weight. Ratios of tumor SUV relative to the SUV of gray matter, brain (including gray and white matter), or white matter were calculated at each imaging time point. Dynamic image data from tumor, gray matter, brain, or white matter were analyzed using a 2-compartment, 4-parameter model applied for the entire duration of imaging, in which delay, K1, distribution volume, k3, and k4 were optimized using a nonlinear optimization method. Parameter estimation for each region included both an early subset of data from a conventional dynamic imaging period (0–60 min) and the full, extended dataset for each region. Results: In 12 of the 19 patients, visual analysis showed that the delayed images better distinguished the high uptake in tumors relative to uptake in gray matter. SUV comparisons also showed greater uptake in the tumors than in gray matter, brain, or white matter at the delayed times. The estimated k4 values for tumors were not significantly different from those for gray matter in early imaging analysis but were lower (P < 0.01) using the extended-time data. Conclusion: The kinetic parameter results confirm the visual and SUV interpretation that tumor enhancement is greater than enhancement of surrounding brain regions at later imaging times, consistent with a greater effect of FDG-6-phosphate degradation on normal brain relative to glioma.

Key Words: delayed 18F-FDG PET • dual time point • glioma • brain neoplasm


Related articles in JNM:

THIS MONTH IN JNM

JNM 2004 45: 8A-9A. [Full Text]  



This article has been cited by other articles:


Home page
JNMHome page
E. C. Ford, J. Herman, E. Yorke, and R. L. Wahl
18F-FDG PET/CT for Image-Guided and Intensity-Modulated Radiotherapy
J. Nucl. Med., October 1, 2009; 50(10): 1655 - 1665.
[Abstract] [Full Text] [PDF]


Home page
J Natl Compr Canc NetwHome page
D. A. Podoloff, D. W. Ball, E. Ben-Josef, A. B. Benson III, S. J. Cohen, R. E. Coleman, D. Delbeke, M. Ho, D. H. Ilson, G. P. Kalemkerian, et al.
NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types
J Natl Compr Canc Netw, June 1, 2009; 7(Suppl_2): S-1 - S-23.
[Abstract] [PDF]


Home page
JNMHome page
W. Chen
Clinical Applications of PET in Brain Tumors
J. Nucl. Med., September 1, 2007; 48(9): 1468 - 1481.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. Muzi, D. A. Mankoff, J. R. Grierson, J. M. Wells, H. Vesselle, and K. A. Krohn
Kinetic Modeling of 3'-Deoxy-3'-Fluorothymidine in Somatic Tumors: Mathematical Studies
J. Nucl. Med., February 1, 2005; 46(2): 371 - 380.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2004 by the Society of Nuclear Medicine.